SEGMENT INFORMATION

6 Months Ended

Apr. 30, 2020

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

10.       SEGMENT INFORMATION

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”).  Reportable operating segments are determined based on the management approach.  The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance.  While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) our legacy Patent Licensing activities.  The following represents selected financial information for our segments for the six and three months ended April 30, 2020 and 2019 and as of April 30, 2020 and October 31, 2019:

	For the six Months Ended April 30,
	2020		2019
Net loss:
CAR-T Therapeutics	$	(1,125,363)	$	(3,517,219)
Cancer Vaccines		(365,867)		-
Anti-Viral Therapeutics		(309,504)		-
Cancer Diagnostics		(3,469,673)		(3,052,355)
Patent Licensing		(4,158)		(971,969)
Total	$	(5,274,565)	$	(7,541,543)
Total operating costs and expenses	$	5,300,006	$	7,826,962
Less non-cash share-based compensation		(2,131,420)		(4,071,614)
Operating costs and expenses excluding     non-cash share-based compensation	$	3,168,586	$	3,755,348
Operating costs and expenses excluding non-cash     share based compensation expense:
CAR-T Therapeutics	$	570,163	$	1,245,681
Cancer Vaccines		165,329		-
Anti-Viral Therapeutics		221,018		-
Cancer Diagnostics		2,208,813		1,417,967
Patent Licensing		3,263		1,091,700
Total	$	3,168,586	$	3,755,348

	For the Three Months Ended April 30,
	2020		2019
Net loss:
CAR-T Therapeutics	$	(495,030)	$	(1,029,934)
Cancer Vaccines		(170,271)		-
Anti-Viral Therapeutics		(309,504)		-
Cancer Diagnostics		(1,679,027)		(1,249,001)
Patent Licensing		(4,158)		(296,999)
Total	$	(2,657,990)	$	(2,574,934)
Total operating costs and expenses	$	2,670,137	$	2,843,234
Less non-cash share-based compensation		(1,110,086)		(1,321,450)
Operating costs and expenses excluding     non-cash share-based compensation	$	1,560,051	$	1,521,784
Operating costs and expenses excluding non-cash     share based compensation expense:
CAR-T Therapeutics	$	223,822	$	444,890
Cancer Vaccines		67,059		-
Anti-Viral Therapeutics		221,018		-
Cancer Diagnostics		1,044,889		658,433
Patent Licensing		3,263		418,461
Total	$	1,560,051	$	1,521,784

	April 30, 2020		October 31, 2019
Total assets:
CAR-T Therapeutics	$	1,011,316	$	2,382,460
Cancer Vaccines		287,831		489,881
Anti-Viral Therapeutics		384,326		-
Cancer Diagnostics		4,089,496		2,921,784
Patent Licensing		151,926		499,568
Total	$	5,924,895	$	6,293,693

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.